SCHEMBL5446246

SCHEMBL5446246

COc1cccc(NC(=O)Nc2sc3c(c2C(N)=O)CCCC3)c1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.73
RXFP1 Q9HBX9 1/20 0.69
KMT2A Q03164 6/20 0.60
RAB9A P51151 1/20 0.60
MEN1 O00255 5/20 0.59
NOD1 Q9Y239 1/20 0.59
RECQL P46063 1/20 0.58
MAPT P10636 3/20 0.57
ALDH1A1 P00352 2/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
TSHR P16473 1/20 0.57
HSD17B10 Q99714 1/20 0.57
LMNA P02545 1/20 0.56
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
THRB P10828 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5455677 0.89 FLT3 (0.74) FLT3RXFP1KMT2ARAB9AMEN1
SCHEMBL5455906 0.87 FLT3 (0.74) FLT3RXFP1KMT2ARAB9AMEN1
SCHEMBL5467554 0.87 FLT3 (0.56) FLT3RXFP1KMT2ARAB9AMEN1
SCHEMBL5455489 0.86 CFTR (0.55) FLT3RXFP1KMT2ARAB9AMEN1
SCHEMBL5453264 0.86 FLT3 (0.71) FLT3KMT2ARAB9AMEN1MAPT
SCHEMBL5446174 0.85 FLT3 (0.71) FLT3RXFP1KMT2ARAB9AMEN1
SCHEMBL8290377 0.84 FLT3 (1.00) FLT3RXFP1KMT2ARAB9AMEN1
SCHEMBL8288770 0.84 FLT3 (0.68) FLT3KMT2ARAB9AMEN1MAPT
SCHEMBL5467889 0.84 FLT3 (0.60) FLT3KMT2ARAB9AMEN1MAPT
SCHEMBL5450860 0.83 MEN1 (0.78) FLT3KMT2ARAB9AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885RXFP1 4595/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.